Render Target: SSR
Render Timestamp: 2024-12-19T20:42:27.493Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-20 06:23:30.648
Product last modified at: 2024-08-30T23:15:07.835Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

SRPIN340 #62630

    Product Information

    Product Usage Information

    SRPIN340 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.43 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 349.4 g/mol
    Purity >98%
    Molecular Formula C18H18F3N3O
    CAS 218156-96-8
    Solubility Soluble in DMSO at 40 mg/mL or ethanol at 25 mg/mL.

    Background

    Serine/arginine-rich protein-specific kinases (SRPKs) 1 and 2 phosphorylate and regulate serine/arginine-rich (SR) proteins that bind and regulate mRNA splicing, playing an important role in post-transcriptional regulation (1). The small-molecule SRPIN340 is an SRPK inhibitor that is highly selective for SRPK1 (Ki = 0.89 mM) and SRPK2. SRPK dysregulation can alter SR protein activity and promote expression of splicing isoforms, leading to increased viral infection or tumorigenic processes. Inhibition of SRPK1 and SRPK2 by SRPIN340 reduces SRp75 protein phosphorylation, leading to suppressed Sindbis virus propagation and reduced HIV production (2). Dose-dependent suppression of hepatitis C virus replication by the inhibitor SRPIN340 has been seen in vitro (1). SRPIN340 treatment of leukemia cells triggered early and late events of apoptosis, and reduced myeloid and lymphoid leukemia cell viability (3). Suppression of VEGF by SRPIN340 inhibited choroidal neovascularization formation in a mouse model, suggesting a possible role for SRPIN340 in treating neovascular age-related macular degeneration (4).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.